Brainstorm Cell Therapeutics Overview
Latest P/E ratio for Brainstorm Cell Therapeutics: -1.18 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-1.18
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, BCLI shows a P/E ratio of -1.18. That is below the Healthcare sector average of 25.9. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 25.9. Brainstorm Cell Therapeutics is at -1.18, which is lower that average. That is roughly 104.6% below the sector mean. Use the comparison chart on this page to see how BCLI stacks up against individual peers as well.
Investors watch BCLI's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Brainstorm Cell Therapeutics's latest reading is -1.18. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Brainstorm Cell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -1.18) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 25.9, while BCLI is at -1.18. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
